Kyowa Hakko Kirin has completed construction of a JPY 7.1 billion ($70 million) monoclonal antibody manufacturing plant in Takasaki City, Gunma, Japan. The facility is slated to begin operations later in 2016 and to come on line with commercial production after 2019. Production will primarily focus on monoclonal antibody drug substances.

The new plant is equipped with a 12,000-liter bioreactor for recombinant animal-cell commercial production of active biopharmaceutical ingredients. The facility is designed for multi-product production in line with cGMP for Japanese, US, and European drug products. It is comprised of four stories with total floor space of approximately 4,000 square meters.

Source: Kyowa Hakko Kirin